98
Complications of Management
Table 25. Safety Considerations for LDL-C–Lowering
Medications
Medication Class Common Side Effects Contraindications*
Microsomal
triglyceride transfer
protein inhibitor
(lomitapide)
Gastrointestinal effects
(ie, diarrhea, nausea,
vomiting, dyspepsia,
abdominal pain) are
common; elevated
hepatic transaminases;
increased hepatic fat;
embryo-fetal toxicity
Pregnancy, concomitant use with
a CPY3A4 inhibitor, moderate
or severe hepatic impairment
or active liver disease including
unexplained persistent abnormal
liver function tests
ANGPTL3
inhibitor
(evinacumab)
Serious hypersensitivity
reactions; embryo-fetal
toxicity
History of serious hypersensitivity
reactions to evinacumab-dgnb or
to any of its excipients
* Contraindications from FDA-approved labeling (available at: http://dailymed.nlm.nih.
gov/dailymed/index.cfm)
†
e Food and Drug Administration has removed pregnancy as a contraindication to statin
therapy.
ANGPTL3 indicates angiopoietin-like protein 3; ATP, adenosine triphosphate; CK,
creatine kinase; HMG-CoA, 3-hydroxy-3-methylglutaryl- coenzyme; HoFH, homozygous
familial hyperlipidemia; mRNA, messenger ribonucleic acid; PCSK9, proprotein convertase
subtilisin/kexin type 9; REMS, Risk Evaluation and Mitigation Strateg y; RNA, ribonucleic
acid; and ULN, upper limit of normal.
(cont'd)
